Replacement of the in vivo Bioassay for Erythropoietin with the in vitro Bioassay
2003
Paik,S.H. | Kim, J.M. | Kwon, G.S. | Park, S.Y. | Huh, J.W. (Central Research Center, Green Cross R D Corporation, Yong-in, Republic of Korea)
In vivo bioassays for biological medicines have been considered final resort to unequivocally assess the biological activities for them because there are some cases in which the biological activities obtained from in vivo bioassay and in vitro bioassay quite differ each other. The in vivo biological activity of EPO depends on its sialic acid contents which confer microheterogeneity-isoforms to this protein.
显示更多 [+] 显示较少 [-]AGROVOC关键词
书目信息
Korean Journal of Biotechnology and Bioengineering
卷
18
期
4
ISSN
1225-7117
页码
pp. 255-260
其它主题
Bioassays
语言
注释
Summaries (En)
11 illus; 6 table; 18 ref
类型
Summary
2005-10-15
AGRIS AP
在Google Scholar上查找
如果您发现与此记录相关的任何错误信息,请联系 agris@fao.org